Blood Based Biomarkers Market Set to Record US$ 41.43 billion by 2035., As Growth by Surge Liquid Biopsy Advances, Cancer Screening, Genomics & Clinical Market Research

Global Blood Based Biomarkers Market reached US$ 10.78 billion in 2025 and is expected to reach US$ 41.43 billion by 2035, growing with a CAGR 14.2% during the forecast period 2026-2035

Ready to scale in the Blood Based Biomarkers Market? Connect with the right partners and unlock new growth opportunities today:- https://www.datamintelligence.com/partner-identification-enquiry/blood-based-biomarkers-market?kb

United States: Recent Industry Developments

✅ March 2026: Thermo Fisher Scientific expanded its liquid biopsy and blood-based biomarker testing capabilities to support early cancer detection and precision medicine applications.

✅ February 2026: Guardant Health advanced development of multi-cancer blood-based biomarker screening technologies aimed at improving non-invasive diagnostics and patient monitoring.

✅ January 2026: Bio-Rad Laboratories introduced enhanced digital PCR solutions designed to improve sensitivity and accuracy in circulating biomarker analysis.

✅ December 2025: Quest Diagnostics strengthened collaborations with healthcare providers to expand adoption of blood-based biomarker testing for oncology and neurological disorders.

Download Free Sample Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/blood-based-biomarkers-market?kb

List of Key Players 2026:

Guardant Health, Inc., GRAIL, Inc., Natera, Inc., Foundation Medicine, Inc., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., QIAGEN, Abbott, Siemens Healthcare Private Limited, bioMérieux, Beckman Coulter, Inc, Illumina, Inc., Bio-Rad Laboratories, Inc., Sysmex Europe SE., Freenome Holdings, Inc., Labcorp, Quest Diagnostics Incorporated., Exact Sciences Corporation., Tempus, Personalis, Inc

Company Evaluation

• Guardant Health, GRAIL, Natera, Foundation Medicine and Tempus lead the blood-based biomarkers market through strong focus on liquid biopsy, ctDNA, MRD and AI-powered precision oncology solutions.

• Roche, Abbott, Siemens Healthineers, Thermo Fisher Scientific and QIAGEN maintain strong market positioning with broad diagnostics portfolios, global laboratory networks and advanced testing platforms.

• Freenome, Exact Sciences, Labcorp, Bio-Rad Laboratories and Illumina are expanding innovation in blood-based screening, biomarker discovery, sequencing and cancer surveillance technologies.

Growth Forecast Projected 2026:

The Global Blood Based Biomarkers Market is anticipated to rise at a considerable rate during the forecast period, between 2026 and 2033. In 2025, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Key Developments 2025-2026:

✅ April 2026: Healthcare and diagnostics companies accelerated development of multi-analyte blood-based biomarker platforms to improve early detection of cancer, neurological disorders, and cardiovascular diseases.

✅ March 2026: Market participants expanded integration of artificial intelligence and machine learning technologies into biomarker analysis workflows to enhance diagnostic accuracy and predictive capabilities.

✅ February 2026: Increased investments in liquid biopsy technologies supported the commercialization of minimally invasive blood-based diagnostic solutions for oncology and chronic disease monitoring.

✅ January 2026: Biopharmaceutical companies strengthened collaborations with diagnostic developers to advance companion diagnostics and personalized treatment strategies using blood-based biomarkers.

✅ December 2025: Growing adoption of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and protein biomarkers improved disease monitoring and therapy response assessment.

✅ November 2025: Regulatory and research initiatives encouraged the expansion of biomarker validation studies aimed at improving clinical reliability, scalability, and standardization across healthcare systems.

✅ October 2025: Advances in high-throughput sequencing, proteomics, and molecular diagnostics enhanced the sensitivity and efficiency of blood-based biomarker testing platforms.

How Our Market Research Process Works:

The global Blood Based Biomarkers Market research report is developed using a comprehensive combination of primary and secondary data sources. The study evaluates a wide range of industry-influencing factors, including government regulations, evolving market dynamics, competitive intensity, and historical performance trends. It also analyzes technological advancements, emerging innovations, and developments across related industries. In addition, the report assesses market volatility, growth opportunities, potential barriers, and key challenges that could impact the future expansion of the Blood Based Biomarkers ecosystem.

Recent Mergers & Acquisitions (M & A) 2025-2026:

• May 2026: Roche entered a definitive merger agreement to acquire PathAI to strengthen AI-driven diagnostics and accelerate biomarker discovery in precision medicine.

• April 2026: QuidelOrtho completed the acquisition of LEX Diagnostics to expand its rapid molecular diagnostics and blood-based biomarker testing capabilities.

• April 2026: CareDx agreed to acquire Naveris in a deal worth up to US$260 million, enhancing blood-based monitoring solutions for viral-mediated cancers.

• February 2026: Guardant Health acquired MetaSight Diagnostics to expand multi-omics liquid biopsy and blood biomarker detection capabilities beyond oncology.

• January 2026: Illumina completed the acquisition of SomaLogic to strengthen proteomics and blood-based biomarker analysis across its multiomics portfolio

Request Strategic Market Customization: https://datamintelligence.com/customize/blood-based-biomarkers-market?kb

Japan: Recent Industry Developments

✅ March 2026: Sysmex Corporation accelerated development of blood-based biomarker technologies for cancer diagnostics and personalized treatment strategies.

✅ February 2026: Fujirebio Holdings, Inc. expanded its biomarker assay portfolio targeting neurodegenerative disease detection through minimally invasive blood testing.

✅ January 2026: Hitachi High-Tech Corporation enhanced diagnostic platform capabilities to support high-throughput blood biomarker analysis in clinical laboratories.

✅ December 2025: Shimadzu Corporation collaborated with research institutions to advance mass spectrometry-based blood biomarker discovery for precision healthcare applications.

Major Focused Key Segmentations 2026:

By Biomarker Type: Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Epigenetic Biomarkers, Cell Free DNA, Circulating Tumor DNA, Circulating Tumor Cells, Multi Biomarker Panels, Others

By Disease Area: Oncology, Cardiovascular Diseases, Neurological Disorders, Infectious Diseases, Autoimmune Diseases, Metabolic Disorders, Prenatal Health, Others

By Application: Screening, Diagnosis, Risk Stratification, Prognosis, Therapy Selection, Companion Diagnostics, Treatment Monitoring, Recurrence Monitoring, Others

By Technology: PCR, NGS, ELISA, Immunoassays, Mass Spectrometry, Proteomics Platforms, Others

By Sample Type: Plasma, Serum, Whole Blood

By End User: Hospitals, Diagnostic Laboratories, Cancer Centers, Pharma and Biotechnology Companies, CROs, Research Institutes

Regional Growth Analysis for Market:

⇥ North America: 42% - Dominates the blood based biomarkers market due to advanced diagnostic infrastructure, strong clinical research activity, and rising adoption of precision medicine.

⇥ Europe: 27% - Growth supported by increasing biomarker-based disease detection, favorable healthcare policies, and expanding oncology research.

⇥ Asia-Pacific: 21% - Rapid expansion driven by growing healthcare investments, rising chronic disease prevalence, and advancements in molecular diagnostics.

⇥ Middle East & Africa: 6% - Emerging adoption supported by improving healthcare infrastructure and increasing awareness of early disease detection.

⇥ South America: 4% - Market growth fueled by expanding diagnostic capabilities and rising demand for non-invasive testing solutions.

We Provide Benefits of the Report:

Chapter 1: Lays the foundation by defining the scope of the report, highlighting core market segments across regions, product types, and applications. It delivers a clear snapshot of current market size, growth potential, and how the industry is expected to evolve in both the near and long term.

Chapter 2: Spotlights the most impactful market insights, unveiling the transformative trends and forces shaping the future of the industry.

Chapter 3: Provides a deep dive into the competitive landscape of , covering revenue shares, strategic initiatives, and notable mergers & acquisitions that are reshaping the market.

Chapter 4: Presents detailed company profiles of leading players featuring financial performance, product portfolios, profit margins, and key milestones that set them apart in the industry.

Chapters 5 & 6: Break down revenue analysis at both regional and country levels, offering precise data on market size, growth drivers, and expansion opportunities across global markets.

Chapter 7: Analyzes the market by product type, spotlighting segment-specific opportunities and helping stakeholders identify untapped, high-growth areas.

Chapter 8 :Explores the market through application-based segmentation, assessing demand across industries and pinpointing downstream sectors with the strongest potential for growth.

Chapter 9: Maps the industry's supply chain in detail, tracing upstream and downstream activities to provide clarity on value creation across the ecosystem.

Chapter 10: Wraps up with a concise summary of the report's key insights distilling the most critical findings and strategic takeaways for decision-makers and stakeholders.

Unlock Full 360° Strategic Report: https://www.datamintelligence.com/buy-now-page?report=blood-based-biomarkers-market?kb

Blood Based Biomarkers Market: Latest Approvals, Regulatory Trials & Government Approvals (2025-2026)

✅ May 2026: Guardant Health received U.S. FDA approval for Guardant360® CDx as a companion diagnostic for Pfizer and Arvinas' VEPPANUTM in ESR1-mutated advanced breast cancer, strengthening the role of blood-based liquid biopsy in precision oncology.

✅ January 2026: Guardant Health secured FDA approval for Guardant360® CDx to identify BRAF V600E-mutant metastatic colorectal cancer patients eligible for BRAFTOVI® combination therapy, expanding non-invasive biomarker-guided cancer treatment selection.

✅ December 2025: Cleveland Diagnostics obtained FDA Premarket Approval (PMA) for IsoPSA®, a blood-based prostate cancer diagnostic test designed to improve biopsy decision-making and early detection of high-grade prostate cancer.

✅ October 2025: Guardant Health received Japanese Ministry of Health, Labour and Welfare (MHLW) approval for Guardant360® CDx as the first blood-based companion diagnostic for ESR1 mutations in metastatic breast cancer patients.

✅ 2025-2026: U.S. FDA and global regulators increased support for liquid biopsy and blood-based companion diagnostics through accelerated approval pathways, breakthrough device programs, and precision oncology initiatives focused on ctDNA, MRD, and multi-cancer early detection (MCED).

✅ 2025-2026: Government-backed cancer research institutes and healthcare organizations expanded clinical trials evaluating blood-based biomarkers for neurological disorders, pancreatic cancer, colorectal cancer, and multi-cancer early detection applications using AI-integrated diagnostic platforms.

✅ 2026: Regulatory agencies increasingly adopted streamlined clinical trial frameworks and real-time oncology data monitoring initiatives to accelerate approval timelines for precision diagnostics and biomarker-driven therapies.

Get Unlimited Market Reports & Strategic Insights: https://www.datamintelligence.com/reports-subscription?kb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.